Orgenesis Inc. (NASDAQ: ORGS) Announces Collaboration with Digilab, Inc. to Develop Industrial 3D Printing Capability for Cellular Structures and Tissues for Clinical Use. Orgenesis Inc. , a developer, manufacturer and service provider of advanced cell therapies, today announced that it has entered into a collaboration agreement with Digilab Inc. to develop a live cell printing process and systems designed to automate the production of three-dimensional live cellular structures and tissues.
Under the Agreement, Orgenesis Inc. will have the exclusive rights to co-develop the process and systems required for its therapeutic collaboration programs and to utilize, market and distribute the new cell printer systems and related products.
Mark Cohen, Senior Partner and Chair of the Life Science Practice Group of Pearl Cohen represents Orgenesis in intellectual property and commercial matters.
